Academic Journal
차세대 완하제 ; New Generation Laxatives
| العنوان: | 차세대 완하제 ; New Generation Laxatives |
|---|---|
| المؤلفون: | 홍성노, 신정은, 홍경섭, 정기욱, 이태희, 이봉은, 박선영, 김성은, 박경식, 최석채, 대한소화기기능성질환ㆍ운동학회 변비 및 항문직장기능 연구회 |
| المساهمون: | Sung Noh Hong, Jeong Eun Shin, Kyoung Sup Hong, Kee Wook Jung, Tae Hee Lee, Bong Eun Lee, Sun-Young Park, Seong-Eun Kim, Kyung Sik Park, Suck Chei Choi, Constipation Research group of the Korean Society of Neurogastroenterology and Motility, 박경식, Park, Kyung Sik, Dept. of Internal Medicine (내과학) |
| بيانات النشر: | School of Medicine |
| سنة النشر: | 2015 |
| المجموعة: | Keimyung University Medical Library: KUMeL Repository |
| الوصف: | A significant proportion of chronic constipation patients are dissatisfied with their treatment. Recently, a number of new medications have been introduced for patients refractory to conventional laxatives, such as prucalopride, lubiprostone, linaclotide, and elobixibat. Prucalopride is a novel gastrointestinal prokinetic agent that acts as a 5-hydroxytryptamine type 4 (5-HT4) agonist. Compared with older nonselective 5-HT4 agonists, the higher selectivity of prucalopride for 5-HT4 receptors can reduce the risk of significant adverse cardiovascular events. Prucalopride improves stool frequency and consistency, and reduces the need for rescue medications. Lubiprostone, a chloride channel activator, increases the secretion of intestinal fluid, improves the stool frequency and consistency, and reduces straining. Linaclotide, a guanylate cyclase-C agonist, is effective in treating patients with chronic constipation and its effect on visceral sensitivity, as shown mainly in animal studies, provides an attractive pharmaceutical option for patients with irritable bowel syndrome with constipation. Elobixibat is an ileal sodium-dependent bile acid transporter inhibitor that blocks the enterohepatic circulation of bile acids, increasing the bile acid concentration in the intestine, which accelerates colonic transit and softens the stool. A phase III trial of the treatment of chronic constipation and irritable bowel syndrome with constipation is underway. The clinical application of new-generation laxatives will contribute to the management of chronic constipation refractory to conventional laxatives. (Korean J Med 2015;88:9-14) Keywords: Constipation; Laxatives; Prucalopride; Lubiprostone; Linaclotide ; open |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 1738-9364 |
| Relation: | 대한내과학회지, Vol.88(1) : 9-14, 2015; oak-bbb-00647; http://kumel.medlib.dsmc.or.kr/handle/2015.oak/37710 |
| DOI: | 10.3904/kjm.2015.88.1.9 |
| الاتاحة: | http://kumel.medlib.dsmc.or.kr/handle/2015.oak/37710 https://doi.org/10.3904/kjm.2015.88.1.9 |
| Rights: | BY_NC_ND ; http://creativecommons.org/licenses/by-nc-nd/2.0/kr |
| رقم الانضمام: | edsbas.752AFFC6 |
| قاعدة البيانات: | BASE |
| تدمد: | 17389364 |
|---|---|
| DOI: | 10.3904/kjm.2015.88.1.9 |